Trials / Completed
CompletedNCT01994850
Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients
A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I/II multicenter single arm non-randomized open label study of the investigational drug, brentuximab vedotin, given in combination with routine chemotherapy (rituximab, cyclophosphamide, doxorubicin and prednisone) every 3 weeks for a total of 6 cycles.
Conditions
- CD30 Positive Primary Mediastinal Large B-cell Lymphoma
- CD30-Positive Diffuse Large B-Cell Lymphoma
- CD30-Positive Gray Zone Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | brentuximab vedotin | Trade name: Adcetris |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2017-08-01
- Completion
- 2019-01-01
- First posted
- 2013-11-26
- Last updated
- 2021-01-05
- Results posted
- 2019-09-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01994850. Inclusion in this directory is not an endorsement.